Oncology Journal Articles

• Management of Toxicities Associated With Bosutinib Review strategies for managing toxicities associated with bosutinib in patients with Ph+ chronic phase CML.
  Annals of Oncology, May 2018
• Effective Promotion of Physical Activity in Cancer Survivors Clinicians are challenged to identify sustainable and accessible physical activity interventions for survivors of cancer.
  Journal of Clinical Oncology, April 2018
• PD-L1 Antibodies for EBV-Positive Gastric Cancer A case report suggests that checkpoint inhibitors may benefit EBV-positive gastric tumors.
  Journal of the National Cancer Institute, April 2018
• SSRI Use and Breast Cancer Survival: Cohort Study Is SSRI use associated with breast cancer mortality?
  Breast Cancer Research, April 2018
• CMS Should Have Required a Randomized Trial of F1CDx Authors give five reasons why CMS should have refrained from coverage of a 324-gene panel offered by Foundation Medicine in the absence of a randomized trial.
  Annals of Oncology, April 2018
• Cardiovascular Care of Breast Cancer Survivors Review the latest strategies for early detection and management of CV disease in patients with a history of breast cancer.
  Journal of Oncology Practice, April 2018
• Management of Chemo-Induced Alopecia With Scalp Cooling Is scalp-cooling technology more effective for decreasing alopecia from taxane-based or anthracycline-based chemotherapy regimens?
  Journal of Oncology Practice, April 2018
• Targeting DNA Repair in SCLC and the Biomarker Landscape Areas of investigation for SCLC include identification of predictive biomarkers, effective combinations to overcome resistance, and strategies for immunotherapy.
  Translational Lung Cancer Research, April 2018
• Prognostic Discussions and Patient-Physician Relationships Does discussing the prognosis hurt the relationship between doctor and patient?
  Journal of Clinical Oncology, April 2018
• Chemotherapy-Associated Neuropathy in Early Breast Cancer Neuropathic symptoms may persist in over 80% of patients receiving adjuvant chemotherapy for early breast cancer.
  Journal of the National Cancer Institute, April 2018
• Watson for Oncology and Breast Cancer Recommendations What is the level of concordance between the artificial intelligence clinical decision-support system Watson for Oncology and a breast cancer tumor board?
  Annals of Oncology, April 2018
• Soaring Cost of Cancer Therapy: Moving Beyond Sticker Shock State experiments with drug pricing may help reform the high-cost of cancer care.
  Journal of Clinical Oncology, March 2018
• Effects of Cryotherapy on Paclitaxel-Induced Neuropathy Wearing frozen flexible gloves and socks during infusion may reduce symptoms of paclitaxel-induced peripheral neuropathy.
  Journal of the National Cancer Institute, March 2018
• Oncofertility Counseling in Breast Cancer Patients With BRCA How should women carrying BRCA 1/2 be counseled about their fertility management?
  Annals of Oncology, March 2018
• HER2 Is Not a Cancer Subtype but Rather a Pan-Cancer Event Research in breast cancer genomics reveals the potential for combining anti-HER2 therapy with anti-androgen agents.
  Breast Cancer Research, March 2018
• Current Standards for Clinical Management of SCLC Review the latest on diagnosis, staging, and management of SCLC.
  Translational Lung Cancer Research, March 2018
• Optimal Duration of Endocrine Therapy for Breast Cancer According to a new study, five years of extended adjuvant letrozole for early breast cancer was not superior to 2.5 years.
  Journal of the National Cancer Institute, March 2018
• The Use of Antidepressants in Oncology Review practical guidance for commonly used antidepressants in patients with cancer.
  Annals of Oncology, March 2018
• Multimodal Imaging of Head and Neck Squamous Cell Carcinoma Review standard and multimodal cross-sectional imaging for evaluation and management of head and neck SCC.
  Cancer Control: Journal of the Moffitt Cancer Center, February 2018
• Alternative Medicine for Cancer and Its Impact on Survival Use of alternative medicine, without the use of conventional cancer therapy, may be associated with greater risk of death in curable cancer.
  Journal of the National Cancer Institute, February 2018